From Financial Modeling Prep: 2025-03-06 08:00:05

Evogene Ltd. (NASDAQ:EVGN) is a leader in computational biology, collaborating with industry giants like Bayer. The company is expected to report a quarterly EPS of -$0.725 and revenue of $3.63 million on March 6, 2025. In 2024, revenue surged to $8.5 million, driven by collaborations and seed sales.

Despite revenue growth, Evogene faces financial hurdles with a negative P/E ratio of -0.35 and an earnings yield of -2.86%. The price-to-sales ratio is 1.01, indicating investor confidence. Enterprise value to sales is 0.97, while debt-to-equity is -2.53. New Chairperson Mr. Nir Nimrodi aims for continued growth under CEO Mr. Ofer Haviv’s leadership.



Read more at Financial Modeling Prep:: Evogene Ltd. (NASDAQ: EVGN) Earnings Preview and F…